Helsinn's oral palonosetron approved in EU
This article was originally published in Scrip
An oral capsule formulation of Helsinn's 5HT3-antagonist palonosetron has been approved by EMA for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. It was approved in the EU in 2005 as an intravenous solution formulation as Onicit and Aloxi. In 2008, the 0.5mg oral capsule was approved in the US. Chemotherapy-induced nausea and vomiting affects the majority of cancer patients undergoing chemotherapy.